Jeffrey Wisch, MD Clinical Investigator Endowment's Fundraising Page

For nearly 40 years, Jeffrey S. Wisch, MD has dedicated his career to caring compassionately for his patients with cancer.  After completing fellowships in hematology and oncology at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, he was recruited to Newton-Wellesley Hospital in 1983 where he became Chief of the Division of Hematology and Medical Oncology in 2013 and later founded and directed the Vernon Cancer Center.  In 2017 Dr. Wisch “came home”, returning to Dana-Farber as Senior Physician in the Gastrointestinal Cancer Center and serving as an integral member of Dana- Farber’s Network Development Team and leading the Gastrointestinal Network Tumor Conferences.

In recognition of Dr. Wisch’s many achievements and contributions to the fields of hematology and medical oncology, we plan to establish an endowment to support dedicated clinicians in the Gastrointestinal Cancer Center who embody Dr. Wisch’s commitment to patient centered cancer care.  The endowment – a fund which will bear his name in perpetuity– will pay tribute to Dr. Wisch in a fashion fitting to his longstanding service and his legacy of leadership and will provide a permanent source of funding for talented physicians working to identify new treatments for patients with gastrointestinal cancer.  

The Jeffrey S. Wisch, MD Clinical Investigator Endowment is integral to the mission of Dana-Farber at large, and particularly the Gastrointestinal Cancer Center, as it will support the talented physicians working to identify new treatments for patients with gastrointestinal cancer. This endowment will support Dana-Farber physicians who are focused on patient-centered research – an area that is great need of support and expansion.  Clinical research is essential to understand and establish the safety and effectiveness of novel treatment regimens and to guide physicians to prescribe the right drug, for the right patient, at the right time. The fastest way new treatment protocols reach the clinic is through robust clinical investigation and trials.  Physician investigators will work on a myriad of projects that will translate basic research into the next generation of breakthrough treatments for patients with gastrointestinal cancers.